REG - BioVentix PLC - Result of AGM

BioventixAnnouncement

06/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241206:nRSF0574Pa&default-theme=true

RNS Number : 0574P  BioVentix PLC  06 December 2024

Bioventix plc

("Bioventix" or the "Company")

Result of AGM

Bioventix plc (AIM: BVXP) a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces that at its Annual General Meeting held
yesterday, all resolutions put to shareholders were duly passed.

 

For further information please contact:

 

 Bioventix plc                                               Tel: 01252 728 001
 Peter Harrison                     Chief Executive Officer
 Bruce Hiscock                      Chief Financial Officer

 Cavendish Capital Markets Limited                           Tel: 020 7220 0500
 Geoff Nash / Elysia Bough          Corporate Finance
 Nigel Birks / Harriet Ward         ECM

 

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGDXBDDCGGDGSU